SG11202107075RA - Selective glucocorticoid receptor modifiers for treating impaired skin wound healing - Google Patents
Selective glucocorticoid receptor modifiers for treating impaired skin wound healingInfo
- Publication number
- SG11202107075RA SG11202107075RA SG11202107075RA SG11202107075RA SG11202107075RA SG 11202107075R A SG11202107075R A SG 11202107075RA SG 11202107075R A SG11202107075R A SG 11202107075RA SG 11202107075R A SG11202107075R A SG 11202107075RA SG 11202107075R A SG11202107075R A SG 11202107075RA
- Authority
- SG
- Singapore
- Prior art keywords
- wound healing
- glucocorticoid receptor
- skin wound
- impaired skin
- treating impaired
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19153026 | 2019-01-22 | ||
EP19170117 | 2019-04-18 | ||
PCT/EP2020/051457 WO2020152193A1 (en) | 2019-01-22 | 2020-01-22 | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107075RA true SG11202107075RA (en) | 2021-08-30 |
Family
ID=69172816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107075RA SG11202107075RA (en) | 2019-01-22 | 2020-01-22 | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220047602A1 (en) |
EP (1) | EP3914249A1 (en) |
JP (1) | JP2022524911A (en) |
KR (1) | KR20210119980A (en) |
CN (1) | CN113382730A (en) |
AU (1) | AU2020211303A1 (en) |
CA (1) | CA3123490A1 (en) |
SG (1) | SG11202107075RA (en) |
WO (1) | WO2020152193A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102571432B1 (en) * | 2023-02-08 | 2023-08-29 | 주식회사 에스씨엘테라퓨틱스 | Composition for treating cancer containing indazolyl ester and amide derivative |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA007483B1 (en) | 1999-04-30 | 2006-10-27 | Пфайзер Продактс Инк. | Use of glucocorticoid receptor modulators and glucocorticoid receptor agonists for preparing medicaments |
RU24858U1 (en) | 2001-10-08 | 2002-08-27 | Открытое акционерное общество "АВТОВАЗ" | STARTER PROTECTION DEVICE |
AU2003221706B2 (en) | 2002-04-11 | 2008-02-28 | Merck Sharp & Dohme Corp. | 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators |
AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
EP1587818A4 (en) | 2003-01-21 | 2010-10-13 | Merck Sharp & Dohme | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
AU2004216182B2 (en) | 2003-02-25 | 2008-11-20 | Merck Sharp & Dohme Corp. | Selective non-steroidal glucocorticoid receptor modulators |
DE602004023926D1 (en) | 2003-04-23 | 2009-12-17 | Merck & Co Inc | SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS |
BRPI0507987A (en) * | 2004-02-25 | 2007-07-31 | Ligand Pharm Inc | glucocorticoid receptor modulating methods and compounds |
JP2008506689A (en) | 2004-07-14 | 2008-03-06 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Intercellular receptor modulator compounds and methods |
DE102004055633A1 (en) | 2004-11-12 | 2006-05-18 | Schering Ag | New 5-substituted quinoline and isoquinoline derivatives are glucocorticoid receptor binders useful for treating inflammatory diseases e.g. alveolitis, Sjogren's syndrome, atopic dermatitis, acute lymphatic leukemia, rhinitis and emesis |
US20090318355A1 (en) * | 2006-02-15 | 2009-12-24 | Chen Thomas T | Compositions and methods for promoting tissue repair and wound healing |
EP2051736A2 (en) | 2006-07-07 | 2009-04-29 | Bausch & Lomb Incorporated | Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
KR20090051076A (en) | 2006-08-07 | 2009-05-20 | 보오슈 앤드 롬 인코포레이팃드 | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases |
ES2403512T3 (en) | 2006-08-07 | 2013-05-20 | Bausch & Lomb Incorporated | Compositions and methods to treat, control, reduce, or improve infections and their sequelae |
CN101528208A (en) | 2006-08-31 | 2009-09-09 | 博士伦公司 | Compositions and methods for treating or preventing glaucoma or progression thereof |
MX2009002544A (en) | 2006-09-11 | 2009-03-20 | Bausch & Lomb | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy. |
JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
WO2008154129A1 (en) | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
EP2016935A1 (en) | 2007-07-09 | 2009-01-21 | Intendis GmbH | Pharmaceutical composition for topical application of poorly soluble compounds |
US20090042936A1 (en) | 2007-08-10 | 2009-02-12 | Ward Keith W | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation |
US20090087443A1 (en) | 2007-09-27 | 2009-04-02 | Bartels Stephen P | Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
EP2062880A1 (en) | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
WO2009103007A2 (en) | 2008-02-13 | 2009-08-20 | Ligand Pharmaceuticals Incorporated | Steroid hormone receptor modulator compounds and methods |
EP2268630A4 (en) | 2008-02-26 | 2011-03-09 | Merck Sharp & Dohme | Hexahydrocyclopentylýf¨indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators |
JP2011513409A (en) | 2008-03-06 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Hexahydrocyclopentyl [f] indazolesulfonamides and their derivatives as selective glucocorticoid receptor modulators |
BRPI0915680A2 (en) | 2008-06-06 | 2019-09-24 | Boehringer Ingelheim Int | glucocorticoid mimetics, methods of preparing them, pharmaceutical compositions, and uses thereof |
US20110077270A1 (en) | 2009-04-21 | 2011-03-31 | Pfeffer Bruce A | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure |
WO2010138421A1 (en) | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | HEXAHYDROCYCLOPENTYL[f]INDAZOLE REVERSED AMIDES AND DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
US20120095055A1 (en) | 2009-06-02 | 2012-04-19 | Merck Sharp & Dohme, Corp. | HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
WO2011031574A1 (en) | 2009-09-08 | 2011-03-17 | Merck Sharp & Dohme Corp. | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
TW201118073A (en) | 2009-10-30 | 2011-06-01 | Merck Sharp & Dohme | Hexahydrocyclopentyl [F] indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators |
US20120316199A1 (en) | 2011-06-07 | 2012-12-13 | Ward Keith W | Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain |
US20130171273A1 (en) * | 2011-12-28 | 2013-07-04 | Kuwait University | Method of treating impaired wound healing in diabetics |
WO2013126156A1 (en) | 2012-02-22 | 2013-08-29 | Bausch & Lomb Incorporated | Nitric oxide donating selective glucocorticoid receptor agonist compounds and ophthalmic compositions |
HUE048410T2 (en) | 2015-09-15 | 2020-07-28 | Leo Pharma As | Non-steroidal glucocorticoid receptor modulators for local drug delivery |
WO2018046685A1 (en) | 2016-09-08 | 2018-03-15 | Bayer Aktiengesellschaft | Quinoline derivatives for treatment of inflammatory skin diseases |
WO2018046678A1 (en) | 2016-09-08 | 2018-03-15 | Bayer Aktiengesellschaft | Formulations containing glucocorticoid receptor agonists |
US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
EP3312608B1 (en) * | 2016-10-24 | 2019-10-02 | Akribes Biomedical GmbH | Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound |
AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
US20200129476A1 (en) * | 2017-04-28 | 2020-04-30 | Akribes Biomedical Gmbh | PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing |
EP3639855A4 (en) * | 2017-06-16 | 2021-03-17 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
EP3641780A4 (en) | 2017-06-20 | 2021-02-24 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
-
2020
- 2020-01-22 AU AU2020211303A patent/AU2020211303A1/en active Pending
- 2020-01-22 WO PCT/EP2020/051457 patent/WO2020152193A1/en unknown
- 2020-01-22 KR KR1020217023228A patent/KR20210119980A/en unknown
- 2020-01-22 SG SG11202107075RA patent/SG11202107075RA/en unknown
- 2020-01-22 CA CA3123490A patent/CA3123490A1/en active Pending
- 2020-01-22 EP EP20700923.4A patent/EP3914249A1/en active Pending
- 2020-01-22 CN CN202080009552.2A patent/CN113382730A/en active Pending
- 2020-01-22 JP JP2021542103A patent/JP2022524911A/en active Pending
-
2021
- 2021-07-20 US US17/380,855 patent/US20220047602A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020211303A1 (en) | 2021-07-15 |
US20220047602A1 (en) | 2022-02-17 |
CA3123490A1 (en) | 2020-07-30 |
KR20210119980A (en) | 2021-10-06 |
CN113382730A (en) | 2021-09-10 |
JP2022524911A (en) | 2022-05-11 |
WO2020152193A1 (en) | 2020-07-30 |
EP3914249A1 (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA186611S (en) | Skin treatment device | |
IL282871A (en) | Systems and methods for skin treatment | |
EP3753435A4 (en) | Human hair fiber treatment agent | |
EP3373825A4 (en) | A wound treatment device for treating a skin wound and a method of treating a skin wound | |
CA189459S (en) | Cosmetic skin treatment apparatus | |
EP3753434A4 (en) | Human hair fiber treatment agent | |
EP3603727A4 (en) | Guide wire, medical device, and treatment method | |
IL272081A (en) | Photodynamic therapy method for skin disorders | |
KR102238777B9 (en) | Wearable wound treatment device | |
GB202103561D0 (en) | Skin treatment device | |
SG11202106794WA (en) | Method for treating lower back pain | |
SG11202107075RA (en) | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing | |
GB2575031B (en) | Skin treatment apparatus | |
EP3710044A4 (en) | Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing | |
EP3608377A4 (en) | Aqueous treatment agent, method for producing aqueous treatment agent, and method of using aqueous treatment agent | |
CA207483S (en) | Skin treatment device | |
GB2589830B (en) | Animal feed, use thereof and method of producing said animal feed | |
EP3937830C0 (en) | Dental splint and method for producing same | |
GB201908076D0 (en) | Skin treatment composition | |
EP3761988A4 (en) | Compositions and methods for treating hyperproliferative skin disorders | |
CA195803S (en) | Skin treatment apparatus | |
CA211610S (en) | Skin treatment system | |
CA207225S (en) | Alopecia treatment device | |
CA204704S (en) | Skin treatment apparatus | |
CA204705S (en) | Skin treatment apparatus |